Navitoclax, which has undergone clinical evaluation in several cancers, inhibits Bcl-2, Bcl-XL and Bcl-w and consequently it is likely to be effective in potentiating the activity of carboplatin in a larger proportion of ovarian cancer patients than ABT-199. Here, BCL2L1 is linked to ovarian carcinoma.